Trastuzumab: observed

142 studies: patients on it are followed, or it is given outside a trial. Page 2 of 2. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.

• Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer PatientsWithdrawnNCT02376413Report a problem
• Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric CancerCompletedNCT02305043Report a problem
• Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and TaxanesStatus unknownNCT02101879Report a problem
• Strain Imaging in Breast Cancer Patients Receiving TrastuzumabCompletedNCT02080390Report a problem
• Early Predictor of Herceptin Cardio Toxicity in Breast Cancer PatientsSuspendedNCT02062983Report a problem
• Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or LapatinibCompletedNCT02056080Report a problem
• H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast CancerCompletedNCT01991340Report a problem
• A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast CancerCompletedNCT01959386Report a problem
• Real World Efficiency of Trastuzumab in Early Breast CancerCompletedNCT01894711Report a problem
• NSABP Biospecimen Discovery ProjectStatus unknownNCT01850628Report a problem
• A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Report a problem
• Identification of Early Markers of Response and Resistance to TrastuzumabCompletedNCT01834950Not applicableReport a problem
• Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)TerminatedNCT01805908Phase 1Report a problem
• Kinetics of Troponin and BNP in Breast Cancer Chemotherapy With Adriamycin and TrastuzumabCompletedNCT01771549Report a problem
• CharactHer. ICORG 12-09, V3TerminatedNCT01722890Report a problem
• Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced CardiotoxicityCompletedNCT01665300Report a problem
• Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast CancerCompletedNCT01572883Report a problem
• Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without TrastuzumabCompletedNCT01562288Report a problem
• Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance ImagingTerminatedNCT01436604Phase 2Report a problem
• Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 YearsCompletedNCT01433926Report a problem
• Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 TrialStatus unknownNCT01424865Report a problem
• Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast CancerCompletedNCT01400438Not applicableReport a problem
• Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinECompletedNCT01291667Report a problem
• An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric CancerCompletedNCT01220934Report a problem
• A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With HerceptinCompletedNCT01152606Report a problem
• Brain Metastasis in Breast Cancer PatientsCompletedNCT01077648Report a problem
• Breast Cancer With Over-expression of erbB2-BRAINSTORMCompletedNCT01064349Report a problem
• Observation Only Study Involving Participants Enrolled in the CHAT TrialStatus unknownNCT01038466Report a problem
• Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving TrastuzumabStatus unknownNCT01022086Report a problem
• CADY Study ICORG 08-01CompletedNCT00968682Report a problem
• Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and TrastuzumabCompletedNCT00875238Report a problem
• Level of HER2-neu Gene Amplification an Response to TrastuzumabStatus unknownNCT00874146Report a problem
• Cardiotoxicity of Adjuvant TrastuzumabCompletedNCT00858039Report a problem
• A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab EmtansineCompletedNCT00833963Report a problem
• Chemotherapeutic Agents in Brain/BreastCompletedNCT00795678Report a problem
• Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast CancerCompletedNCT00755313Report a problem
• Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer PatientsCompletedNCT00740532Report a problem
• Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)TerminatedNCT00679874Report a problem
• IRS Proteins and Trastuzumab ResistanceCompletedNCT00657345Report a problem
• Detection of Chemotherapy Induced CardiotoxicityCompletedNCT00636844Report a problem
• PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast CancerCompletedNCT00362973Report a problem
• An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neuCompletedNCT00153218Report a problem

← Trastuzumab